ABSTRACT
In multiple sclerosis (MS) as in other diseases, rational treatment depends on a thorough understanding of the etiology and pathogenesis. Research into the pathogenesis of MS and especially the rapidly growing number of different animal models are beginning to reveal a remarkable heterogeneity and complexity of the pathogenic mechanisms of inflammatory demyelinating central nervous system (CNS) disease1-3. In view of these developments, it seems likely that much more refined classifications can be developed in the future for the disease we today call MS. Clearly, this will improve the chances for a more differentiated therapeutic approach.
